Does Rallies summarize JUNS news?

Yes. Rallies summarizes JUNS news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.

Is JUNS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for JUNS. It does not provide personalized investment advice.

JUNS (Jupiter Neurosciences, Inc. Common Stock) Stock Analysis - News

Jupiter Neurosciences, Inc. Common Stock (JUNS) is a publicly traded Healthcare sector company. As of May 20, 2026, JUNS trades at $0.35 with a market cap of $12.06M and a P/E ratio of -1.38. JUNS moved +7.81% today. Year to date, JUNS is -68.32%; over the trailing twelve months it is -43.16%. Its 52-week range spans $0.31 to $19.51. Rallies surfaces JUNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in JUNS news today?

Jupiter Neurosciences Secures $100M Term Sheet for ALA-002 MDMA U.S. Rights: Jupiter Neurosciences agreed to pay $3.33 million upfront and issue $1.83 million in stock for exclusive U.S. rights to ALA-002, plus milestone payments and royalties, closing in 90 days. ALA-002 is a patented non-racemic MDMA NCE engineered to enhance cardiovascular safety and reduce abuse liability in a $6–15 billion psychedelic therapeutics market.

JUNS Key Metrics

Key financial metrics for JUNS
Metric	Value
Price	$0.35
Market Cap	$12.06M
P/E Ratio	-1.38
EPS	$-0.25
Dividend Yield	0.00%
52-Week High	$19.51
52-Week Low	$0.31
Volume	194.68M
Avg Volume	0
Revenue (TTM)	$21.80K
Net Income	$-8.64M
Gross Margin	0.00%

Latest JUNS News

Jupiter Neurosciences Secures $100M Term Sheet for ALA-002 MDMA U.S. Rights — May 20, 2026
Jupiter Neurosciences to Showcase JOTROL Platform at 9:00 AM ET Wall Street Summit May 5 — May 4, 2026
Jupiter Neurosciences Highlights FDA-Cleared Phase IIa Parkinson’s Trial and Nugevia™ 25% Repeat Buys — Mar 2, 2026
Jupiter Neurosciences Tapped to Showcase Phase IIa and Nugevia™ Updates at Mar-a-Lago Investor Dinner — Feb 25, 2026
Jupiter Neurosciences Defers $6M Convertible Note Repayments to April 2026 — Feb 23, 2026

Recent JUNS Insider Trades

Silva Alison D. bought 250 (~$256.575) on Jul 1, 2025.
Silva Alison D. bought 250 (~$257.175) on Jul 1, 2025.
Silva Alison D. bought 250 (~$258.5) on Jul 1, 2025.

JUNS Analyst Consensus

JUNS analyst coverage data. Average price target: $0.00.

Common questions about JUNS

What changed in JUNS news today?: Jupiter Neurosciences Secures $100M Term Sheet for ALA-002 MDMA U.S. Rights: Jupiter Neurosciences agreed to pay $3.33 million upfront and issue $1.83 million in stock for exclusive U.S. rights to ALA-002, plus milestone payments and royalties, closing in 90 days. ALA-002 is a patented non-racemic MDMA NCE engineered to enhance cardiovascular safety and reduce abuse liability in a $6–15 billion psychedelic therapeutics market.
Does Rallies summarize JUNS news?: Yes. Rallies summarizes JUNS news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is JUNS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for JUNS. It does not provide personalized investment advice.